CAR-T CELL THERAPY -
PATIENT GUIDE

CAR-T cell therapy is an adoptive cell therapy that genetically engineers a patient's own T-cells to express a chimeric antigen receptor (CAR) — a synthetic protein that directs T-cells to recognize and destroy cancer cells. First conceptualized by Zelig Eshhar in the late 1980s and brought to clinical success by Carl June's group at Penn in 2010–2012, the first FDA approval (Kymriah for pediatric B-ALL) followed in August 2017.

“CAR-T therapy is a personalized, living medicine — a one-of-a-kind biological drug made from each patient's own cells, capable of persisting and acting long after a single infusion.”

• Adoptive Cell Therapy

  A class of cancer therapy using immune cells collected from the patient, manipulated outside the body, and reinfused to target cancer — CAR-T is the most clinically advanced form of this approach.

• The CAR Construct

  A chimeric antigen receptor combines an extracellular scFv antibody domain (which recognizes the cancer antigen), a hinge/transmembrane region, and intracellular signaling domains (CD3-zeta + co-stimulatory) — all in a single synthetic protein.

• MHC-Independent Killing

  Unlike natural T-cell receptors that require MHC presentation, the CAR's scFv domain recognizes unprocessed antigens directly on cancer cell membranes — bypassing a major immune evasion mechanism used by tumors.

• Serial Killing & Persistence

  After killing the first target cell, the CAR-T cell survives, proliferates, and kills successive targets — a phenomenon called serial killing. The cells can persist for years, acting as a living ongoing therapy.

Each generation adds signaling components that enhance persistence, proliferation, and tumour-microenvironment resistance. All currently approved products are second-generation CARs.

CAR-T manufacturing integrates cell collection, genetic engineering, expansion, quality control, and cold-chain logistics — all within a 3–6 week window.

1. 1

   Leukapheresis — Collecting T-Cells

   The patient is connected to an apheresis machine that separates white blood cells from whole blood. The collected leukocytes are quality-assessed and shipped in temperature-controlled containers to the CAR-T manufacturing facility — in China or abroad.

2. 2

   T-Cell Activation & Viral Transduction

   T-cells are activated using anti-CD3/CD28 antibodies, then transduced with a viral vector (typically lentiviral) carrying the CAR gene. The CAR integrates permanently into the T-cell DNA and is passed to all daughter cells.

3. 3

   Expansion in Bioreactors

   CAR-T cells are expanded over 7–14 days using IL-2 and growth factors to reach the target dose of 50 million to several hundred million cells per infusion.

4. 4

   Quality Control & Release Testing

   Sterility, identity (confirmed CAR+ T-cells), viability, potency, and mycoplasma testing must all pass specifications before release. A significant percentage of autologous manufacturing runs fail QC — most often in heavily pre-treated patients with poor T-cell health.

5. 5

   Cold-Chain Shipping to Treatment Centre

   The cryopreserved product is shipped back to the treating hospital under strict temperature-controlled conditions. Chinese manufacturers including Fosun Kite and Legend Biotech operate end-to-end cold-chain logistics for international patients.

6. 6

   Lymphodepletion Chemotherapy

   Fludarabine and cyclophosphamide are given for 3 days (5–3 days before infusion) to deplete the patient's immune cells, eliminate suppressor cells, and create a homeostatic cytokine environment that drives CAR-T expansion in vivo.

7. 7

   CAR-T Infusion & Post-Infusion Monitoring

   Infusion is similar to a blood transfusion — IV, 30–60 minutes. CRS and ICANS monitoring begins immediately: daily temperature checks, blood tests every 2–3 days, ferritin/CRP/LDH/cytokine panels as early CRS warning signals. Inpatient monitoring: 2–4 weeks.

CAR T-cell therapy is a personalized cancer treatment. First, doctors collect the patient’s T cells, which are important immune cells, through a blood collection process. These cells are then modified in a specialized laboratory so they can recognize a specific marker on cancer cells. After modification, the CAR T cells are multiplied in large numbers and carefully tested for quality. The patient may receive short chemotherapy to prepare the body. Finally, the CAR T cells are infused back into the patient, where they search for and attack cancer cells under close medical monitoring.

“CAR T-cell therapy collects a patient’s immune cells, genetically trains them to recognize cancer, expands them in a lab, and then infuses them back to attack cancer cells under specialist supervision.”

As of 2025, nine CAR-T products are FDA-approved. Not all are available in all countries — patients outside the US and Europe should verify local availability or explore China and clinical trial pathways.

Key response data from pivotal trials underpinning FDA approvals. All in heavily pre-treated, relapsed/refractory patients.

• 9FDA-Approved CAR-T Products (2025)Covering B-ALL, DLBCL, FL, MCL, and multiple myeloma.
• 97.9%Highest ORR — Carvykti in r/r MyelomaCARTITUDE-1 trial; best published CAR-T response rate to date.
• 3–6 weeksAutologous Manufacturing TimeChinese manufacturers (Fosun Kite, Legend Biotech) operate at the faster end of this range.
• 30–50%Cost Saving in China vs USAFor NMPA-approved equivalent CAR-T products at leading Chinese haematology centres.
• 21.8Median Duration of ResponseAmong responders in CARTITUDE-1, the median duration of response was 21.8 months, which pairs well with the headline ORR and adds an important durability number.
• 1 monthMedian Time to First ResponseResponses appeared quickly, with a median time to first response of 1 month in the FDA label, which is a useful practical benchmark for patient-facing content.

CAR-T has a unique side-effect profile unlike chemotherapy or checkpoint immunotherapy. Both major toxicities are graded, monitored, and — in experienced centres — managed predictably.

Extending CAR-T to solid tumours is the most important unsolved challenge in the field. Three barriers — antigen heterogeneity, poor tumour infiltration, and an immunosuppressive microenvironment — require next-generation solutions. China leads global clinical trial activity for solid tumour CAR-T.

• GD2 — Neuroblastoma & Osteosarcoma

  Highly expressed on neuroblastoma, osteosarcoma, and melanoma. Anti-GD2 CAR-T has shown early responses in pediatric neuroblastoma (Great Ormond Street, US centres). Chinese groups have active GD2 programmes.

• HER2 — Breast, Gastric, Glioblastoma

  Overexpressed in HER2+ breast, gastric, and other cancers. Must be carefully dosed to avoid pulmonary on-target toxicity. Promising early data in HER2+ glioblastoma, where the brain environment provides partial immune privilege.

• Mesothelin — Mesothelioma, Ovarian, Pancreatic

  Expressed on mesothelioma, ovarian, lung adenocarcinoma, and pancreatic cancer. Phase I trials show safety and modest activity. Chinese centres have active mesothelin CAR-T programmes.

• EGFR / EGFRvIII — NSCLC, Glioblastoma

  EGFRvIII is a tumour-specific mutant expressed on glioblastoma — not on normal tissue. Wild-type EGFR programmes in NSCLC and colorectal cancer have been pioneered by Chinese groups at the PLA General Hospital. Early published data are promising.

Between 2016 and 2024, China registered more CAR-T clinical trials than any other country. Multiple domestic products are NMPA-approved, with Chinese companies leading proprietary manufacturing innovations.

“"China's CAR-T programme is reshaping global access to cell therapy—offering more approved products, broader clinical trials, and significantly lower costs than any other country. For patients with relapsed blood cancers who have run out of standard options, China represents one of the most important treatment frontiers in the world today."”

• Fosun Kite (Yescarta equivalent)

  Fosun Kite's axicabtagene ciloleucel (axi-cel) is NMPA-approved for r/r DLBCL and FL — the Chinese equivalent of Yescarta, manufactured domestically with established cold-chain logistics for international patients.

• Legend Biotech / Carvykti (BCMA)

  Legend Biotech (Nanjing) developed the LCAR-B38M nanobody-based BCMA CAR-T (now Carvykti globally). This Chinese-origin product achieved the highest ORR ever published for a CAR-T therapy: 97.9% in r/r myeloma.

• Gracell's FasT CAR Platform

  Gracell Biotechnologies' proprietary FasT CAR platform reduces standard manufacturing time from 14–21 days to 22–36 hours — potentially transforming access for patients who cannot wait weeks for product manufacturing.

• CD7 CAR-T for T-Cell Malignancies

  Chinese groups (Wuhan Union Hospital) have pioneered CD7-targeted CAR-T for T-cell ALL and T-cell lymphoma — a previously untreatable indication with dramatic published Phase I/II results.

For most international patients from South Asia, the Middle East, and Southeast Asia, China is the most practical access pathway — combining NMPA-approved products, domestic manufacturing, and substantially lower cost.

CancerFax has navigated patients from South Asia, the Middle East, and Southeast Asia through every stage of the CAR-T journey at Chinese cancer centres.

1. 1

   Clinical Eligibility Assessment

   A thorough review of diagnosis, treatment history, performance status, and disease severity to determine eligibility for NMPA-approved CAR-T products or open Chinese clinical trials.

2. 2

   Product & Trial Matching

   Assessment of which NMPA-approved product (CD19 for B-cell malignancies, BCMA for myeloma) is most appropriate, or which clinical trial provides access to an indication not yet commercially available.

3. 3

   Hospital Matching

   Referral to the most appropriate Chinese haematology centre: Peking University People's Hospital, Chinese PLA General Hospital, or Hebei Yanda Lu Daopei Hospital — matched to disease type, required product, and clinical complexity.

4. 4

   Leukapheresis Coordination

   Determining whether leukapheresis can be performed in the patient's home country (product shipped to China) or requires travel to China — then coordinating the procedure, cold-chain shipping, and manufacturer receipt.

5. 5

   Visa, Travel & In-Country Support

   Medical visa invitation letter, accommodation near the treating centre, airport transfers, daily clinical communications, family updates, and practical support throughout the 6–10 week treatment and monitoring period.

6. 6

   Post-Treatment Follow-Up

   Coordination of response assessment, MRD testing, and follow-up with the patient's home haematologist — ensuring continuity of care after return from China.

Explore in-depth guides on every aspect of CAR-T cell therapy.

Frequently Asked Questions

The most common questions from patients and families exploring CAR-T cell therapy.